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Abstract
Hyponatremia is the most frequent electrolyte disorder encountered in hospitalized patients. Several studies have 
demonstrated that hyponatremia is a negative prognostic factor in different clinical scenarios. Noteworthy, not 
only severe and acute hyponatremia has been associated with an increased risk of mortality, but also moderate of 
even mild chronic hyponatremia may increase the risk of death. This has been demonstrated in different categories 
of patients, including cancer patients. There is growing evidence that both progression free survival and overall 
survival are significantly reduced in cancer patients with hyponatremia compared to patients with normonatremia. 
One important, and still open, question is whether the worse outcome associated with hyponatremia in cancer 
patients is directly attributable to the electrolyte disorder itself or might be a sign of the severity of the underlying 
disease. With regard to this point, some basic research studies suggested that low sodium concentration 
stimulates per se cancer cells proliferation and invasiveness. Recent clinical evidence appears to indicate that the 
correction of hyponatremia is an independent and favourable prognostic factor in cancer patients. Admittedly, 
robust confirmatory data from clinical practice are needed, in order to validate the hypothesis that cancer patients 
may die for hyponatremia and not just with hyponatremia.
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INTRODUCTION
Hyponatremia, which is the most frequent electrolyte disorder in hospitalized patients[1], frequently occurs 
also in cancer patients at different stages of disease. For instance, a recent retrospective study, performed 
at a large University Hospital in Germany in inpatients receiving specialist palliative care, showed that 
the prevalence of hyponatremia was 38.7% (e.g., 275 out of 710 patients) and that low serum sodium 
concentration [Na+] was associated with symptom severity[2]. Several studies have demonstrated that 
hyponatremia is a negative prognostic factor in different clinical scenarios. Noteworthy, not only severe 
and acute hyponatremia has been associated with an increased risk of mortality, but there is evidence that 
also moderate of even mild chronic hyponatremia may increase the risk of death. This has been shown for 
instance in a large cohort study, which included more than 50,000 inpatients at a teaching academic medical 
center. This study showed that mildly reduced serum [Na+] was associated with an increased in-hospital 
mortality. In addition, each mmol/L reduction of serum [Na+] increased the risk of death by 2.3%[3]. Among 
different clinical settings, hyponatremia has been associated with an increased risk of death in patients with 
heart failure[4-6], acute myocardial infarction[7,8], pneumonia[9], cirrhosis[10,11], renal failure[12], pulmonary 
embolism[13], intracerebral hemorrhage[14], in the elderly[15], in intensive care patients[16], in patients 
undergoing surgery[17] or cardiovascular procedures[18]. An extensive meta-analysis, including more than 
850,000 patients, of whom 17.4% with hyponatremia, confirmed an increased mortality rate associated with 
reduced serum [Na+][19].
The literature addressing cancer patients indicated that hyponatremia is a negative prognostic factor also in 
this subset of patients. This chapter will review the published data, so far, with the exception of patients with 
lung cancer, which is the specific topic of another chapter. 
HYPONATREMIA AS A PROGNOSTIC AND PREDICTIVE FACTOR IN CANCER PATIENTS
Ten years ago Waikar et al.[7] published the results of a prospective cohort study, conducted in two teaching 
hospitals in Boston, MS, in which the association between serum [Na+] and mortality was investigated. 
The main outcome measures were in-hospital 1-year and 5-year mortality of patients with hyponatremia vs 
those with normal serum [Na+]. Patients with hyponatremia had higher in-hospital mortality rates either 
at 1 year and at 5 years, even when serum [Na+] was only slightly reduced (130-134 mmol/L). Among the 
different clinical subgroups that were analyzed, the risk of in-hospital mortality was significantly higher in 
hyponatremic patients with metastatic cancer [hazard ratio (HR) 2.05, 95% confidence interval (CI): 1.67-
2.53] compared to normonatremic patients.
Shortly after, another study addressed predictors of inpatients mortality in an acute palliative care unit at the 
M. D. Anderson Cancer Center of the University of Texas. Of the 500 cancer patients admitted, 124 (25%) 
died[20]. Hyponatremia was one of the multiple predictors of a negative outcome (HR 3.02, 95%CI: 1.76-5.17, P < 
0.001), together with younger age, hypernatremia, high blood urea nitrogen, high heart rate, high respiration 
rate, and supplemental oxygen use. 
A retrospective analysis of patients admitted at the same Cancer Center during a three months period in 2006, 
aiming to correlate hyponatremia with 90-day mortality, was performed[21]. Serum [Na+] was categorized 
into four groups, e.g., normonatremia (serum [Na+] 135-147 mmol/L), mild (130-134 mmol/L), moderate 
(120-129 mmol/L), and severe (< 120 mmol/L) hyponatremia. In all hyponatremic groups the risk of 
mortality at 90 days was higher than in normonatremic patients (HR for mild, moderate, and severe 
hyponatremia: 2.04 (95%CI: 1.42-2.91; P < 0.01); 4.74 (95%CI: 3.21-7.01; P < 0.01), and 3.46 (95%CI: 1.05-11.44; 
P = 0.04), respectively. Although the authors recognized limitations to the study (observational, retrospective 
study, inability to adjust for all comorbid conditions), and the fact that it has not been proven that 
hyponatremia correction can reduce mortality, these data further confirmed the clear relationship between 
hyponatremia and increased mortality in cancer patients. 
An Italian study performed in Ancona analyzed 105 consecutive cancer patients, affected by gastrointestinal, 
lung, breast, female genital tract, renal, brain tumors, and sarcoma, hospitalized during a 6 month period[22]. 
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Median overall survival (OS) from the day of hospitalization was 50 days. Hyponatremic patients had a 
significantly reduced OS (P = 0.0255) compared to normonatremic patients. In addition, the authors reported 
that the presence of metastases was associated with a reduced OS (P = 0.0418). Similar results were obtained by 
Castillo et al.[23], who analyzed a population of patients with lymphoma, breast cancer, colorectal cancer, small 
cell and non-small cell lung cancer. Hyponatremia was negatively associated with OS in all types of tumor, but 
the highest HRs were found in lymphoma (HR 4.5, P < 0.01) and in breast cancer (HR 3.7, P < 0.1).
In a retrospective cohort study, performed in a single center, 204 cancer patients affected by hyponatremia 
secondary to the syndrome of inappropriate anti-diuresis (SIAD), which is the most common cause of 
hyponatremia in oncology, were selected. Malignancies included lymphoma, leukemia, colorectal, breast, 
lung, pancreas, prostate, head and neck, bladder, esophagus, gastric cancer. About 75% of patients had 
malignancy-associated SIAD, whereas in roughly 25% SIAD was due to other etiologies (e.g., medications, 
pulmonary infections, pain or nausea). The authors found that patients with malignancy-associated SIAD 
had a significantly shorter median survival (58 days vs. 910 days, P < 0.001). The authors hypothesized that 
the cause of SIAD in cancer patients might represent a useful prognostic factor[24]. 
A correlation between hyponatremia and a negative outcome was found also in patients with terminal 
cancer. A retrospective observational study conducted in a tertiary hospital palliative care unit in the 
Republic of Korea reported that, in addition to serum C-reactive protein (HR 1.22; P < 0.001) and Palliative 
Performance Scale (HR 0.69, P < 0.001), serum [Na+] ≤ 125 mmol/L was associated with a reduced survival 
time (HR = 1.91; P < 0.001) among 576 terminally ill patients (pancreatic/hepatobiliary, gastric, colorectal, 
lung cancer)[25].
In a retrospective study performed at a University Hospital in China, among patients affected by 
nasopharyngeal carcinoma, glioma or oral cancer, that had been subjected to radiotherapy and developed 
radiation-induced brain necrosis, the risk of progression (i.e., increase of edema area ≥ 25% on the MRI) was 
three-fold higher in patients with hyponatremia compared to those with normonatremia. Thus, the authors 
claimed that hyponatremia may be considered as a potential predictor for the progression of radiation-
induced brain necrosis and recommended that hyponatremia is appropriately managed also in these 
patients[26].
Other authors addressed their attention to a different subset of cancer patients, i.e., those who develop 
spontaneous tumor lysis syndrome, that induces acute uric acid nephropathy. This is a rare, yet potentially 
fatal complication in cancer patients, and it is important to determine the relevance of potential prognostic 
predictors. Although only 12 patients developed this condition among the 1,073 patients admitted with acute 
renal failure to a single hospital during a period of four years, hyponatremia and hypoalbuminemia on the 
first day of admission were the best predictors of poor prognosis[27]. 
An interesting retrospective cohort study performed in a primary care setting in Copenhagen, Denmark, 
examined another issue, i.e., the predictive role of hyponatremia on the subsequent development of cancer. This 
type of analysis is facilitated in countries, like Denmark, which have a National Patient Registry. The authors 
showed that there is a level-dependent increased risk to develop cancer in patients with hyponatremia. The 
cumulative incidence increased in patients with mild (serum [Na+] 130-135 mmol/L), moderate (125-129 mmol/
L) or severe hyponatremia (< 125 mmol/L) [HR 1.32 (95%CI: 1.26-1.39), 1.31 (95%CI: 1.17-1.47), 1.77 (95%CI: 1.39-
2.24), respectively] at 12 months, compared to normonatremic subjects. When different cancers types were 
analyzed separately, this finding was confirmed in head and neck, pulmonary and gastrointestinal cancer[28].
Some studies on the role of hyponatremia in cancer have addressed specific cancer types. With regard to 
renal cell carcinoma (RCC), 212 newly diagnosed patients with localized RCC undergoing nephrectomy were 
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recruited in a study aiming to examine the prognostic value of hematologic and biochemical parameters, 
and other tumor-related factors. Multivariate analyses showed that preoperative serum [Na+] was an 
independent predictor of OS and disease-free survival, when considered either as a continuous variable or 
when patients were grouped based on a cut-off of serum [Na+] of 139 mmol/L (median value). The estimates 
of 5-year OS were 67.6% (95%CI: 54.2-80.9) and 44.3% (95%CI: 32.8-55.8) for patients with serum [Na+] above 
or below 139 mmol/L respectively[29]. A Danish study addressed patients with metastatic RCC, divided into 
two independent cohorts of 120 patients/each. In each cohort 20% and 14% of patients had hyponatremia. 
Patients with hyponatremia at baseline had a median OS of 5.5 and 4.8 months in the two cohorts, whereas 
patients with normonatremia at baseline had a median OS of 18.6 and 16.9 months, respectively[30]. In 
multivariate analysis, hyponatremia proved to be an independent prognostic factor (HR 1.90, 95%CI: 1.1-3.2, 
P = 0.014), together with increased neutrophils (HR 1.75, CI: 1.1-2.8, P = 0.018), lactate dehydrogenase > 1.5 
ULN (HR 2.09, 95%CI: 1.3-3.3, P = 0.002), and number of metastatic sites (+3) (HR 1.92, 95%CI: 1.3-2.9, P = 
0.003). Finally, hyponatremia was significantly associated with lack of response to treatment in both cohorts. 
A more recent Japanese study confirmed that hyponatremia appears to be a powerful prognostic predictor 
in patients with metastatic RCC treated with tyrosine-kinase inhibitors following radical nephrectomy[31]. 
In this study both progression-free survival (PFS) and OS were significantly lower in hyponatremic patients 
(median 10.0 and 20.9 months, respectively) than in normonatremic patients (median 28.4 and 38.5 months, 
respectively).
Reduced serum [Na+] was indicated as a negative prognostic marker also in patients with gastric cancer 
and bone marrow metastases [HR 4.57; 95%CI: 1.99-10.52; P < 0.001][32] and in patients with hepatocellular 
carcinoma[33].
WHY IS HYPONATREMIA ASSOCIATED WITH A WORSE OUTCOME IN CANCER PATIENTS?
Clinical data clearly indicate that hyponatremia may be viewed as a predictor of a negative outcome in 
cancer patients. Admittedly, one open question is whether the reduced PFS and OS, described by a number 
of publications, is directly attributable to the electrolyte disorder itself or might be a sign of the severity of 
the underlying disease. With regard to this point, a Belgian prospective study on hyponatremia in cancer 
patients, published almost 20 years ago, suggested that the increase mortality rate observed in cancer 
patients with hyponatremia (19.5% vs 6.3% in normonatremic partients) was not apparently due to reduced 
serum [Na+], thus indicating that hyponatremia was to be considered as a marker of general debility in 
advanced disease[34]. A retrospective review (entitled “Mortality and serum sodium: do patients die from 
or with hyponatremia?”) of the medical records of patients admitted to a teaching hospital in Rochester, 
NY, for different pathologies and who died after developing hyponatremia, also suggested that the main 
determinant of the observed deaths was likely the severity of the underlying illness rather than the degree 
of hyponatremia[35]. Similarly, a retrospective study that included patients diagnosed with SIAD in a 
community hospital in Israel showed that long-term survival was determined by SIAD etiology rather than 
by hyponatremia severity[36].
Recently, a study performed at two teaching hospitals in Italy and one teaching hospital in England demonstrated 
that serum [Na+] normalization during first-line therapy is an independent prognostic factor for OS and PFS in 
patients with non-small cell lung cancer[37]. Similarly, normalization of serum [Na+] was associated with a better 
prognosis in patients with metastatic RCC treated with everolimus[38]. These findings are in agreement with the 
results of a meta-analysis that analyzed articles reporting the outcome of patients with different diseases in which 
hyponatremia had been corrected. The meta-analysis indicated that any improvement of hyponatremia was 
associated with a reduced risk of overall mortality [HR = 0.57 (0.40-0.81)][39].
Anyway, this issue is still a matter of debate and prospective randomized studies in cancer patients with 
hyponatremia, aiming to evaluate whether correction of hyponatremia can counteract the progression of the 
disease, are necessary. 
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Interestingly, some basic research studies have evaluated whether a microenvironment with a low [Na+] may 
affect cell proliferation and invasion ability. A study performed in prostate cancer cells in vitro demonstrated 
for instance that the exposure to a slightly hypertonic milieu induced a dormant state. Cell dormancy 
represents a limiting step of the metastatic process by preventing the proliferation of isolated cells outside 
the primary tumor. Conversely, the authors demonstrated that in the presence of a hypotonic milieu, 
obtained for instance by reducing [Na+] in the culture medium, cell cloning significantly increased[40]. 
Another study showed that low [Na+] reduced neuroblastoma cell adhesion and increased invasion ability[41]. 
A micro-array analysis was performed, in order to analyze the gene expression pattern of cells exposed to 
low [Na+] compared to normal [Na+]. Among the genes that had different expression levels in the presence 
of reduced [Na+], the heme-oxigenase 1 gene (HMOX-1), a marker of oxidative stress, was the gene with the 
greatest variation. In fact, HMOX-1 gene expression showed a 200-fold increase in cells exposed to low [Na+]. 
Immunocytochemistry for HMOX-1 protein confirmed these results. It is known that oxidative stress favors 
carcinogenesis, cancer growth and invasion, angiogenesis, and overall creates a permissive environment for 
cancer cells[42]. Accordingly, selective inhibition of HMOX-1 has been proposed as a therapeutic target for 
cancer treatment[43]. Although additional studies are needed in order to confirm these data, in view of the 
above described results from basic research it can be hypothesized that also in vivo low [Na+] might promote 
cancer cell progression through the same mechanisms. If so, then we might probably say that patients die 
not only with hyponatremia, but also for hyponatremia.  
CONCLUSION
In recent years evidence indicating that hyponatremia is a predictor of a worse outcome in cancer patients 
has accumulated. There is emerging evidence, mainly from basic research studies at this time, that 
hyponatremia may by itself increase the risk of mortality of patients, rather than being a simple bystander of 
the progression of the disease. However, robust confirmatory data from clinical practice are certainly needed 
in order to definitively validate the hypothesis that cancer patients may die for hyponatremia.
Meanwhile, the author is truly convinced that it is worth to correct hyponatremia in patients, including 
cancer patients, because of the overall beneficial effect on the quality of life, which includes clinical 
improvement, such as amelioration of neurocognitive and motor performance, reduced length of stay in the 
hospital and re-admission probability[44-46]. 
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